Hsbc Holdings PLC acquired a new position in shares of Azenta, Inc. (NASDAQ:AZTA – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 44,004 shares of the company’s stock, valued at approximately $1,108,000.
A number of other institutional investors also recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd boosted its stake in shares of Azenta by 2,067.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 802 shares of the company’s stock worth $27,000 after buying an additional 765 shares during the period. Osaic Holdings Inc. grew its holdings in shares of Azenta by 44.9% during the second quarter. Osaic Holdings Inc. now owns 1,242 shares of the company’s stock worth $39,000 after buying an additional 385 shares during the last quarter. Rockefeller Capital Management L.P. increased its position in Azenta by 98.0% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,392 shares of the company’s stock valued at $46,000 after acquiring an additional 689 shares during the period. Van ECK Associates Corp increased its position in Azenta by 141.2% in the 4th quarter. Van ECK Associates Corp now owns 1,585 shares of the company’s stock valued at $53,000 after acquiring an additional 928 shares during the period. Finally, State of Wyoming purchased a new stake in Azenta during the 1st quarter valued at approximately $38,000. 99.08% of the stock is currently owned by institutional investors and hedge funds.
Azenta Stock Down 0.9%
Shares of Azenta stock opened at $32.65 on Tuesday. Azenta, Inc. has a 52-week low of $15.93 and a 52-week high of $41.73. The company’s 50-day simple moving average is $29.14 and its 200-day simple moving average is $25.18. The firm has a market cap of $1.43 billion, a price-to-earnings ratio of -11.83 and a beta of 1.36.
Analysts Set New Price Targets
AZTA has been the topic of several analyst reports. Weiss Ratings upgraded Azenta from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. Needham & Company LLC upped their price target on Azenta from $33.00 to $37.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $41.20.
About Azenta
Azenta, Inc (NASDAQ: AZTA) is a life sciences technology company specializing in sample management, cryogenic storage and genomic services for research and clinical applications. Formerly the Life Sciences division of Brooks Automation, Azenta provides integrated solutions that enable customers to store, track and analyze biological samples with high levels of automation, data integrity and efficiency. Its offerings span automated storage systems, biorepository management software and end‐to‐end sample tracking workflows.
In addition to hardware and informatics platforms for sample storage, Azenta’s Genomics business delivers next‐generation sequencing (NGS), DNA synthesis, and molecular biology services.
Featured Articles
- Five stocks we like better than Azenta
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding AZTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Azenta, Inc. (NASDAQ:AZTA – Free Report).
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
